publication . Article . 2017

Different effects of paliperidone and risperidone therapy on blood lipid and Hcy metabolism as well as endocrine hormones in patients with schizophrenia

Bei-Fang Fan; Ze-Hui Li; Shuo Yang; Cai-Hong Gao;
Open Access English
  • Published: 01 Nov 2017 Journal: Journal of Hainan Medical University (issn: 1007-1237, eissn: 1007-1237, Copyright policy)
  • Publisher: Editorial Board of Journal of Hainan Medical University
Abstract
Objective: To explore the different effects of paliperidone and risperidone therapy on blood lipid and Hcy metabolism as well as endocrine hormones in patients with schizophrenia. Methods: A total of 118 patients with schizophrenia who were treated in the hospital between December 2014 and February 2017 were collected as the research subjects and divided into control group and study group by random number table, each group with 59 cases. Control group received risperidone therapy, observation group received paliperidone therapy, and the differences in the levels of blood lipid indexes, Hcy metabolism indexes and endocrine hormones were compared between the two g...
Subjects
free text keywords: Schizophrenia, Paliperidone, Risperidone, Hcy, Endocrine hormone, Medicine, R
Download from
17 references, page 1 of 2

[1] Gaspar HA, Breen G. Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach. Sci Rep 2017; 7(1): 12460.

[2] Stürup AE, Jensen HD, Dolmer S, Birk M, Albert N, Nielsen M, et al. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial. Trials 2017; 18(1): 445.

[3] Chen H, Fan Y, Zhao L, Hao Y, Zhou X, Guan Y, et al. Successful treatment with risperidone increases 5-HT 3A receptor gene expression in patients with paranoid schizophrenia - data from a prospective study. Brain Behav 2017; 7(9): e00798.

[4] Dammerman R, Kim S, Adera M, Schwarz A. A Phase 1, OpenLabel, Single dose pharmacokinetic study in stabilized patients with schizophrenia following risperidone implant. Psychopharmacol Bull 2017; 47(4): 36-40.

[5] Potkin SG, Loze JY, Forray C, Baker RA, Sapin C, Peters-Strickland T, et al. Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study. PLoS One 2017; 12(8): e0183475. [OpenAIRE]

[6] Savitz AJ, Xu H, Gopal S, Nuamah I, Hough D, Mathews M. Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study. Int Clin Psychopharmacol 2017; 32(6): 329-336.

[7] Smesny S, Gussew A, Biesel NJ, Schack S, Walther M, Rzanny R, et al. Glutamatergic dysfunction linked to energy and membrane lipid metabolism in frontal and anterior cingulate cortices of never treated first-episode schizophrenia patients. Schizophr Res 2015; 168(1-2): 322- 329. [OpenAIRE]

[8] Vincenzi B, Stock S, Borba CP, Cleary SM, Oppenheim CE, Petruzzi LJ, et al. A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism. Schizophr Res 2014; 159(2-3): 395-403.

[9] Chen J, Pan X, Qian M, Yang S. Efficacy and metabolic influence on blood-glucose and serum lipid of ziprasidone in the treatment of elderly patients with first-episode schizophrenia. Shanghai Arch Psychiatry 2017; 29(2): 104-110. [OpenAIRE]

[10]Di Lorenzo R, Amoretti A, Baldini S, Soli M, Landi G, Pollutri G, et al. Homocysteine levels in schizophrenia patients newly admitted to an acute psychiatric ward. Acta Neuropsychiatr. 2015; 27(6): 336-344.

[11]Song X, Fan X, Li X, Kennedy D, Pang L, Quan M, et al. Serum levels of BDNF, folate and homocysteine: in relation to hippocampal volume and psychopathology in drug naïve, first episode schizophrenia. Schizophr Res 2014; 159(1): 51-55.

[12]Misiak B, Frydecka D, Slezak R, Piotrowski P, Kiejna A. Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. Metab Brain Dis 2014; 29(3): 661-670. [OpenAIRE]

[13]Nishi A, Numata S, Tajima A, Kinoshita M, Kikuchi K, Shimodera S, et al. Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull 2014; 40(5): 1154-1163. [OpenAIRE]

[14]Bulut SD, Bulut S, Atalan DG, Tulaci RG, Türker T, Gürçay E, et al. The effect of antipsychotics on bone mineral density and sex hormones in male patients with schizophrenia. Psychiatr Danub 2016; 28(3): 255-262. [OpenAIRE]

[15]Zhang B, Deng L, Wu H, Lu X, Peng L, Wu R, et al. Relationship between long-term use of a typical antipsychotic medication by Chinese schizophrenia patients and the bone turnover markers serum osteocalcin and β-CrossLaps. Schizophr Res 2016; 176(2-3): 259-263.

17 references, page 1 of 2
Abstract
Objective: To explore the different effects of paliperidone and risperidone therapy on blood lipid and Hcy metabolism as well as endocrine hormones in patients with schizophrenia. Methods: A total of 118 patients with schizophrenia who were treated in the hospital between December 2014 and February 2017 were collected as the research subjects and divided into control group and study group by random number table, each group with 59 cases. Control group received risperidone therapy, observation group received paliperidone therapy, and the differences in the levels of blood lipid indexes, Hcy metabolism indexes and endocrine hormones were compared between the two g...
Subjects
free text keywords: Schizophrenia, Paliperidone, Risperidone, Hcy, Endocrine hormone, Medicine, R
Download from
17 references, page 1 of 2

[1] Gaspar HA, Breen G. Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach. Sci Rep 2017; 7(1): 12460.

[2] Stürup AE, Jensen HD, Dolmer S, Birk M, Albert N, Nielsen M, et al. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial. Trials 2017; 18(1): 445.

[3] Chen H, Fan Y, Zhao L, Hao Y, Zhou X, Guan Y, et al. Successful treatment with risperidone increases 5-HT 3A receptor gene expression in patients with paranoid schizophrenia - data from a prospective study. Brain Behav 2017; 7(9): e00798.

[4] Dammerman R, Kim S, Adera M, Schwarz A. A Phase 1, OpenLabel, Single dose pharmacokinetic study in stabilized patients with schizophrenia following risperidone implant. Psychopharmacol Bull 2017; 47(4): 36-40.

[5] Potkin SG, Loze JY, Forray C, Baker RA, Sapin C, Peters-Strickland T, et al. Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study. PLoS One 2017; 12(8): e0183475. [OpenAIRE]

[6] Savitz AJ, Xu H, Gopal S, Nuamah I, Hough D, Mathews M. Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study. Int Clin Psychopharmacol 2017; 32(6): 329-336.

[7] Smesny S, Gussew A, Biesel NJ, Schack S, Walther M, Rzanny R, et al. Glutamatergic dysfunction linked to energy and membrane lipid metabolism in frontal and anterior cingulate cortices of never treated first-episode schizophrenia patients. Schizophr Res 2015; 168(1-2): 322- 329. [OpenAIRE]

[8] Vincenzi B, Stock S, Borba CP, Cleary SM, Oppenheim CE, Petruzzi LJ, et al. A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism. Schizophr Res 2014; 159(2-3): 395-403.

[9] Chen J, Pan X, Qian M, Yang S. Efficacy and metabolic influence on blood-glucose and serum lipid of ziprasidone in the treatment of elderly patients with first-episode schizophrenia. Shanghai Arch Psychiatry 2017; 29(2): 104-110. [OpenAIRE]

[10]Di Lorenzo R, Amoretti A, Baldini S, Soli M, Landi G, Pollutri G, et al. Homocysteine levels in schizophrenia patients newly admitted to an acute psychiatric ward. Acta Neuropsychiatr. 2015; 27(6): 336-344.

[11]Song X, Fan X, Li X, Kennedy D, Pang L, Quan M, et al. Serum levels of BDNF, folate and homocysteine: in relation to hippocampal volume and psychopathology in drug naïve, first episode schizophrenia. Schizophr Res 2014; 159(1): 51-55.

[12]Misiak B, Frydecka D, Slezak R, Piotrowski P, Kiejna A. Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. Metab Brain Dis 2014; 29(3): 661-670. [OpenAIRE]

[13]Nishi A, Numata S, Tajima A, Kinoshita M, Kikuchi K, Shimodera S, et al. Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull 2014; 40(5): 1154-1163. [OpenAIRE]

[14]Bulut SD, Bulut S, Atalan DG, Tulaci RG, Türker T, Gürçay E, et al. The effect of antipsychotics on bone mineral density and sex hormones in male patients with schizophrenia. Psychiatr Danub 2016; 28(3): 255-262. [OpenAIRE]

[15]Zhang B, Deng L, Wu H, Lu X, Peng L, Wu R, et al. Relationship between long-term use of a typical antipsychotic medication by Chinese schizophrenia patients and the bone turnover markers serum osteocalcin and β-CrossLaps. Schizophr Res 2016; 176(2-3): 259-263.

17 references, page 1 of 2
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue